our targeted oral peptide for psoriasis and ulcerative colitis; JNJ-4804, our co-antibody therapeutic for inflammatory bowel disease; Aticaprant for adjunctive major depressive disorder; and nipocalimab for rheumatoid arthritis. In med tech, we completed enrollment...
We also deployed, announced, or committed to over $32 billion in strategic value-creating inorganic growth opportunities in the last 12 months. This amount includes larger transactions such as Shockwave, Proteologix, the NM26 bispecific antibody, V-Wave, the planned acquisition of Intra-Cellular Th...
during the first half of 2024, Johnson & Johnson has deployed approximately $17 billion in strategic value-creating inorganic growth opportunities. This includes Shockwave, Proteologix and the NM26 bispecific antibody transaction announced last